We have located links that may give you full text access.
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Long-term effect of dalteparin in the prevention of neovascularization of iris in recent-onset central retinal vein occlusion.
Archives of Iranian Medicine 2008 September
BACKGROUND: To compare the long-term effect of dalteparin in the prevention of neovascularization of iris in recent-onset central retinal vein occlusion with that of aspirin.
METHODS: A randomized controlled clinical trial was conducted on patients with central retinal vein occlusion of less than 30 days duration. Patients in the dalteparin group received subcutaneous dalteparin 100 IU/kg twice a day for 10 days, and then 100 IU/kg once a day for another ten days. In the aspirin group the patients received 100 mg aspirin daily throughout the study.
RESULTS: Forty seven patients were enrolled, 24 in the dalteparin group and 23 in the aspirin group, and were followed up for one year. One (4.1%) of the 24 patients in dalteparin group, and 9 (39.1%) of 23 patients in aspirin group developed iris neovascularization. the difference was significant (P=0.0001). The visual outcomes of the two groups were compared, and a significant difference was found (P=0.016).
CONCLUSION: Patients treated with dalteparin within 30 days of the onset of central retinal vein occlusion were less likely to develop neovascularization of iris. There was also a significant difference in the visual acuity between two groups.
METHODS: A randomized controlled clinical trial was conducted on patients with central retinal vein occlusion of less than 30 days duration. Patients in the dalteparin group received subcutaneous dalteparin 100 IU/kg twice a day for 10 days, and then 100 IU/kg once a day for another ten days. In the aspirin group the patients received 100 mg aspirin daily throughout the study.
RESULTS: Forty seven patients were enrolled, 24 in the dalteparin group and 23 in the aspirin group, and were followed up for one year. One (4.1%) of the 24 patients in dalteparin group, and 9 (39.1%) of 23 patients in aspirin group developed iris neovascularization. the difference was significant (P=0.0001). The visual outcomes of the two groups were compared, and a significant difference was found (P=0.016).
CONCLUSION: Patients treated with dalteparin within 30 days of the onset of central retinal vein occlusion were less likely to develop neovascularization of iris. There was also a significant difference in the visual acuity between two groups.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app